Financial Data and Key Metrics Changes - Iterum generated net product sales of $0.4 million in Q3 2025, which included initial stocking at specialty pharmacies [21] - Total operating expenses were $8.1 million in Q3 2025, compared to $4.9 million in Q3 2024, reflecting increased commercialization activities [21][22] - The net loss on a US GAAP basis was $9 million for Q3 2025, compared to a net loss of $6.1 million for Q3 2024 [24] Business Line Data and Key Metrics Changes - The launch of Orlyvah began on August 20, 2025, with over 280 prescriptions generated by more than 100 unique prescribers by November 12, 2025 [9][12] - Approximately 40% of Orlyvah prescriptions have been filled through payer approval processes, aligning with expectations [10] Market Data and Key Metrics Changes - Orlyvah's access now reaches 16% of insured lives, with increasing adoption by employer groups and payer formularies [16] - A signed rebate agreement with a top Medicare Part D pharmacy benefit manager allows Orlyvah to be added to formularies for coverage beginning in 2026 or 2027 [15] Company Strategy and Development Direction - The company plans to raise additional capital to support ongoing commercialization efforts and potentially expand into high-value territories [19] - Iterum aims to generate revenue in excess of expenses and become self-funding over the next couple of years [19] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the feedback from physicians, payers, and patients regarding Orlyvah, indicating a positive trajectory for revenue growth [20] - The company expects modest sales in Q4 2025 and anticipates net product revenue for 2026 to be between $5 million and $15 million [18] Other Important Information - Iterum's cash and cash equivalents at the end of September 2025 were $11 million, providing an operating runway into Q2 2026 [24][25] - The company has reduced its in-person field team to 10 representatives and is augmenting efforts with virtual sales representatives [14] Q&A Session Summary Question: Will the company report specific launch metrics in the coming quarters? - The company plans to report metrics such as prescriptions, growth, and number of physicians to track the launch [27][28] Question: Can the company provide more details on payer coverage and uptake? - Feedback from physicians has been positive, particularly regarding Orlyvah's ability to keep patients out of the hospital [31][32] Question: What marketing strategies are being considered to drive uptake? - The company is focusing on field organization investments and is considering social media and other marketing channels for future engagement [40][52]

Financial Data and Key Metrics Changes - Lifeward reported revenue of $6.2 million in Q3 2025, a slight increase of approximately 1.1% from $6.1 million in Q3 2024, and an 8% increase from $5.7 million in Q2 2025 [6][7] - GAAP gross profit for Q3 2025 was $2.7 million, or 43.7% of revenue, compared to $2.2 million, or 36.2% of revenue in Q3 2024, driven by lower production costs [9][10] - GAAP operating loss for Q3 2025 was $3.1 million, a slight improvement from $3.2 million in Q3 2024, while non-GAAP operating loss was $3 million compared to $4.1 million in the same period last year [11][12] Business Line Data and Key Metrics Changes - Revenue from traditional products, including ReWalk, MyoCycle, and ReStore, totaled $3.1 million in Q3 2025, up 24% from $2.5 million in Q3 2024, driven by increased Medicare-related sales [8] - Revenue from AlterG products decreased to $3.1 million in Q3 2025 from $3.6 million in Q3 2024, primarily due to timing factors [8] Market Data and Key Metrics Changes - Lifeward expanded patient access with the first Medicare Advantage commercial revenue for the ReWalk 7 personal exoskeleton and received CE mark approval, enhancing access to the European market, which represents about 40% of the global addressable exoskeleton opportunity [4][12] - The company closed the quarter with a pipeline of over 117 qualified leads for ReWalk in the U.S. and 49 leads in Germany, including 33 active rentals [8] Company Strategy and Development Direction - The company is focused on rebuilding fundamentals, defining strategic direction, and improving operational discipline, with a commitment to creating durable long-term value [3][5] - Lifeward is exploring global expansion opportunities and strategic partnerships to enhance financial position and market access [13][14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing transformation and the potential for growth, emphasizing the importance of operational efficiencies and a focused sales approach [5][12] - The company reaffirmed its full-year 2025 guidance, expecting revenue in the range of $24-$26 million and a projected non-GAAP net loss of $12-$14 million [12] Other Important Information - Lifeward completed a $3 million loan agreement with AuraMed to enhance liquidity and support the transformation plan [4][12] - The company ended Q3 2025 with $2 million in cash and cash equivalents and no debt, indicating a stable financial position [11][12] Q&A Session Summary Question: Breakdown of rental systems for ReWalk - Lifeward confirmed that there are 33 active rentals, all in Germany [17] Question: Impact of collaboration with CoreLife - Management noted that the partnership with CoreLife is progressing well, with a growing pipeline and learning from training processes [19] Question: Percentage of revenue from Medicare - Medicare accounts for approximately 50% of total revenue, specifically for ReWalk products [21][24] Question: Revenue contribution from ReWalk within traditional product sales - Revenue from ReWalk products is approximately $2.9 million within the $3.1 million of traditional product sales [25] Question: Changes needed for AlterG to stabilize - Management indicated a need for a dedicated sales team for AlterG to regain focus and improve sales performance [38] Question: Introduction of ReWalk 7 in Germany - The company has a solid pipeline with 33 active rentals that are expected to convert to sales within three to six months [39] Question: Comfort level regarding financial stability - Management expressed optimism about the turnaround potential and the strength of the product portfolio, indicating a positive outlook for overcoming financial challenges [42]

Financial Data and Key Metrics Changes - The company ended Q3 2025 with a cash balance of $14.3 million and raised an additional $1.2 million since the quarter end, providing a runway through 2026 [23] - The net loss for Q3 2025 was $2.9 million, or $0.65 per share, compared to a net loss of $1.8 million, or $0.46 per share, for Q3 2024 [23] - For the nine months ended September 30, 2025, the net loss was $9.9 million, or $2.39 per share, compared to $8.3 million, or $2.24 per share for the same period in 2024 [23] Business Line Data and Key Metrics Changes - The company presented updated clinical data from the ongoing trial of agenT-797, showing a median overall survival of approximately 23 months in patients with relapsed or refractory solid tumors when combined with PD-1 therapies [4] - Observations included complete remission in a patient with metastatic testicular cancer and durable partial responses in other difficult-to-treat cancers, demonstrating the potential of agenT-797 to restore immune function [5][6] Market Data and Key Metrics Changes - The company has established a strategic partnership with the University of Wisconsin Carbone Cancer Center to advance the iNKT program in immune reconstitution following stem cell transplantation [10] - The company is preparing for a global phase II trial in acute pulmonary dysfunction with multi-drug resistant infections, targeting critically ill patients [12] Company Strategy and Development Direction - The company aims to redefine immune recovery in cancer, infection, critical illness, and transplantation, focusing on innovative partnerships and disciplined capital use [9][22] - The leadership team has been strengthened with the onboarding of Dr. John Holcomb and Dr. Therese Hammond, enhancing the company's strategic direction [24] Management's Comments on Operating Environment and Future Outlook - Management highlighted the importance of building public-private partnerships and emphasized the potential of iNKT cells in various therapeutic areas, including cancer and critical illness [9][22] - The company expects to have multiple clinical programs actively enrolling patients by this time next year, with early readouts emerging from ongoing studies [26] Other Important Information - The company executed an at-the-market sales agreement, leveraging a significant increase in equity price to access cash while limiting dilution to shareholders [25] - The company is preparing for a first-in-human phase I study with minimal capital impact, supported by public-private grants [11] Q&A Session Summary Question: Expansion of the combination therapy cohort - Management acknowledged the potential to expand the cohort for patients previously treated with anti-PD-1 therapies and indicated plans for a phase two study [28][29] Question: Timing for the launch of the severe pulmonary disease trial - Management confirmed that the activation phase is underway, targeting patient enrollment by early next year [32] Question: Details on GVHD and pulmonary disease trials - Management provided insights into the endpoints being evaluated, including GVHD presence and 28-day mortality, emphasizing the potential for significant clinical benefits [33][35][39]

Financial Data and Key Metrics Changes - AtlasClear reported revenue of $4.25 million for Q1 2026, representing a 52% increase year over year [6][9] - Operating loss narrowed to $877,000 from $941,000 in the prior year [6][9] - Net loss was $440,000 compared to a net income of $10.7 million in the same period last year, which included non-cash gains from fair value adjustments [6][9] - Total assets grew to $73.6 million, up 21% from June 30 [6][9] - Stockholders' equity improved to $6.86 million from a negative $6.8 million three months prior, marking a swing of over $13 million [4][9] Business Line Data and Key Metrics Changes - The subsidiary Wilson-Davis & Co. continued to show profitability with strong commission, clearing, and stock loan results [5][6] - Revenue components included commissions of $2.33 million, vetting fees of $0.37 million, clearing fees of $0.71 million, and other revenues of $0.83 million [9] Market Data and Key Metrics Changes - The market for smaller financial institutions remains dynamic, with a focus on efficient clearing, funding, and technology infrastructure [5] - AtlasClear is positioned to capitalize on the growing demand for technology-driven clearing and banking solutions [13] Company Strategy and Development Direction - The company aims to leverage its strengthened balance sheet and new growth funding to integrate its technology stack and expand stock loan and margin lending programs [12] - Plans include advancing the acquisition of Commercial Bancorp, which will provide low-cost funding and a regulated bank charter [12] - The company is focused on enhancing technology and pursuing selective M&A opportunities to broaden client reach and product capabilities [12][13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to grow without significant dilution from the recent financing [17][18] - The company is optimistic about the regulatory approval process for the Commercial Bancorp acquisition and sees it as a strategic asset for future growth [26][27] - Management highlighted the importance of digital assets and plans to integrate them into their offerings, viewing 2026 as a pivotal year for crypto-related revenues [22][25] Other Important Information - The company secured $20 million in new institutional financing, which includes convertible notes and equity units, enhancing liquidity and growth potential [4][12] - The leadership team has been strengthened with the addition of a new CFO and an independent director [7] Q&A Session Summary Question: Can you elaborate on the $20 million Funicular financing and its structure? - The financing includes a convertible note with an 11% coupon and a unit offering comprised of equity and warrants, which is expected to support growth without significant dilution [17][18] Question: Can you provide an update on compliance with NYSE listing requirements given the share price is below a dollar? - The company is compliant with NYSE American standards, which do not have a dollar threshold, allowing continued growth without immediate concerns [19][20] Question: What is the company's digital asset strategy going forward? - Digital assets are a primary focus, with plans to integrate them into the platform and potential acquisitions in the space to enhance offerings [22][25] Question: Can you provide an update on the Commercial Bancorp acquisition and regulatory progress? - The company plans to file with the Fed for approval by January 31 and is optimistic about the integration and long-term goals post-acquisition [26][27][30]

Financial Data and Key Metrics Changes - Revenue for Q3 2025 grew 32% year-over-year, reaching $0.6 million [20] - Operating expenses decreased by 10% year-over-year, and net cash used in operating activities was down 33% compared to the prior year [20][21] - Net loss improved by 8% for the quarter and down 20% for the first three quarters compared to the prior year [20][21] Business Line Data and Key Metrics Changes - The company signed two significant agreements: one with Werfen for anti-phospholipid syndrome (APS) and another with Hologic for co-marketing the Nu.Q Discover service [4][8] - The Nu.Q NETs assay is being validated by Werfen for clinical utility in APS patients, with early results showing promise [5][6] - Hologic has already made its first sale of the Nu.Q Discover service, indicating strong initial traction [34] Market Data and Key Metrics Changes - The total addressable market (TAM) for APS is estimated at approximately $85 million annually, which is a strategic entry point for the company's NETs platform [8][27] - The combined TAM for cancer and sepsis diagnostics is approximately $25 billion annually, presenting substantial revenue opportunities [25] Company Strategy and Development Direction - The company aims to achieve cash neutrality by aligning income with expenditures through licensing agreements and milestone payments [21][24] - There is a focus on expanding the Nu.Q VET cancer test globally, with centralized lab automation being a key priority to accelerate revenue growth [22][23] - The company is actively pursuing additional licensing agreements in the human diagnostic space, mirroring its successful strategy in the veterinary market [24] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the partnerships with Werfen and Hologic, viewing them as transformative for future growth [34][36] - The company anticipates significant progress in clinical utility studies and expects to see more licensing deals in the near future [11][39] - Management acknowledged the challenges of the current market but emphasized the importance of delivering on commercialization plans [81][83] Other Important Information - The company is in discussions with around 10 leading diagnostic and liquid biopsy companies for potential partnerships [10] - The CAPTCHA-seq technology is expected to revolutionize liquid biopsy methods, with promising early results in cancer detection [12][16] Q&A Session Summary Question: Size of the anti-phospholipid syndrome market - The TAM for APS is estimated at $85-$90 million annually, which is a good starting point for the company's NETs platform [27][28] Question: Contribution of the Werfen partnership to Q3 revenue - The Werfen partnership has not yet contributed to revenue as they are still validating the assay on clinical samples [32] Question: Expectations for additional partnerships in 2026 - Management expects to close several additional partnerships in 2026, although the timing is uncertain [37][39] Question: Breakdown of product revenues - Product revenues are still lumpy, with significant contributions from both the Nu.Q VET tests and the Discover kits [45] Question: Conditions for milestone payments related to feline cancer testing - Milestone payments are contingent upon the publication of a paper, which is currently in progress [66][72]

Financial Data and Key Metrics Changes - The company is facing unprecedented demand growth for power, primarily driven by artificial intelligence and data centers, as well as re-onshoring of US manufacturing and growing residential demand for power [5][10] - The average active coal, gas, and nuclear plant in the U.S. is over 40 years old, indicating a need for new baseload power generation capacity [4] Business Line Data and Key Metrics Changes - The company is pivoting towards conventional gas power with post-combustion carbon capture (PCC) technology, which is seen as a more immediate opportunity compared to its oxycombustion technology [18][25] - The first phase of the Project Permian in West Texas is targeting a levelized cost of energy (LCOE) below $80 per megawatt hour, with plans to scale to 300 megawatts and beyond [22][30] Market Data and Key Metrics Changes - The U.S. has over 50 years of ultra-low-cost natural gas reserves, positioning it uniquely compared to other countries [11][12] - The market is increasingly favoring natural gas as a reliable and scalable power source, especially in the context of AI and data center demands [10][11] Company Strategy and Development Direction - The company aims to transform natural gas into the lowest-cost form of clean, reliable power while ensuring affordability and reliability [10][25] - A partnership with Entropy is being pursued to accelerate the deployment of clean gas projects in the U.S., leveraging their expertise in PCC technology [20][27] Management's Comments on Operating Environment and Future Outlook - Management emphasizes the urgency of building new generation capacity to meet rising power demands, particularly in light of the AI race [8][10] - The company acknowledges the challenges posed by rising costs and the need for a strategic pivot to capitalize on near-term opportunities while maintaining long-term goals [17][18] Other Important Information - The company has identified high-quality locations for its projects, which are essential for economic viability [15][16] - The partnership with Entropy is expected to enhance the company's ability to deploy clean gas power projects quickly and efficiently [20][27] Q&A Session Summary Question: What makes NET Power uniquely positioned to take advantage of this opportunity? - The company possesses a fundamental understanding of both power generation and subsurface resources, along with high-quality sites for deployment [36][39] Question: Why partner with Entropy? - The partnership is based on Entropy's operational experience and proven technology, which allows for the acceleration of clean power projects in the U.S. [42][46] Question: What is the financing strategy for phase one and follow-on projects? - The financing strategy involves leveraging proven technologies for project financing, reducing the equity capital burden compared to previous plans [48][50]

Financial Data and Key Metrics Changes - Working capital increased from $500,000 in Q3 2024 to $15 million in Q3 2025 [4] - Net income turned positive at $300,000 compared to a loss of $6.4 million in the previous year [4] - EBITDA was positive at $1.9 million, with adjusted EBITDA at $0.8 million [4] - Digital assets, specifically Bitcoin holdings, rose by 143% to 97 Bitcoin, while total digital currency value increased by 213% year over year to $15.4 million [4] Business Line Data and Key Metrics Changes - Energy revenue grew by 112% year over year to $8.7 million [5] - Cost of revenue and depreciation decreased by $9.3 million year to date [5] Market Data and Key Metrics Changes - The company has over $90 million in cash, Bitcoin, Ethereum, and equivalents, representing the strongest liquidity in its history [5] - Current power availability includes 55 megawatts in Alabama and 141.7 megawatts in upstate New York, totaling close to 200 megawatts for 2026 [6] Company Strategy and Development Direction - The company is transitioning into AI infrastructure, with plans for a scalable high-density AI compute ecosystem [6] - The ARMS 200 Tier 3 AI pod assembly began in Q4 2025, with deployment across all Tier 3 sites starting in January 2026 [5] - The NeoCloud Z GPU-as-a-Service platform is set to launch in January 2026, targeting smaller AI developers and research institutions [16] Management's Comments on Operating Environment and Future Outlook - Management expects AI revenues to reach approximately $65 million in 2026, driven by colocation and GPU-as-a-Service offerings [8][9] - The company is positioned for growth with a focus on AI infrastructure and energy sales, which accounted for over 35% of revenues in Q3 2025 [9] Other Important Information - The company has no long-term debt and is completely debt-free, with the lowest payables recorded [10] - The ARMS platform is designed for rapid deployment and customization, allowing for faster scaling compared to traditional hyperscale solutions [12][13] Q&A Session Summary Question: What are your expectations in AI revenues in 2026 and 2027? - Management estimates roughly $50 million in revenues from colocation and an additional $15 million from GPU-as-a-Service, totaling about $65 million in AI revenues for 2026 [8][9] Question: What are the current debts? - The company confirmed it holds no long-term debts and has no obligations that could harm its financial position [10] Question: How is your current cash holding? - The company holds over $90 million, primarily in cash, with some holdings in Bitcoin and Ethereum [11] Question: Can you please describe the ARMS AI-ready modular solution platform? - The ARMS platform is a proprietary modular system developed for rapid deployment, designed for various chip types, primarily NVIDIA [12][13] Question: Can you please go into some detail on your relationship with Supermicro Computers Inc.? - The company has developed a strong partnership with Supermicro for optimized service racks and software integration, which aids in reducing operational costs [14][15] Question: Can you please describe the retail compute platform NeoCloud, who the potential customers or end users will be? - NeoCloud is aimed at smaller AI developers and research institutions, expected to contribute 20%-25% of total revenue, with a focus on high-margin GPU-as-a-Service offerings [16][17]

Financial Data and Key Metrics Changes - The company ended Q3 2025 with $369.6 million in cash and cash equivalents, reporting operating expenses of $103 million, which includes $18.3 million in non-cash stock-based compensation [24][25] - Excluding stock-based compensation, operating expenses were $85.3 million, reflecting ongoing investments in infrastructure to support regulatory approval and commercial readiness [25] Business Line Data and Key Metrics Changes - The company is focused on advancing apitegromab for spinal muscular atrophy (SMA) and has initiated dosing in a phase two OPAL trial for infants and toddlers under the age of two [16][18] - The phase III SAPPHIRE study demonstrated apitegromab's potential to reverse the trajectory of SMA, showing significant benefits in motor function [13][20] Market Data and Key Metrics Changes - Annual revenue for current SMA treatments is trending to approximately $5 billion globally, indicating a growing demand for treatments [20][21] - There are an estimated 35,000 people with SMA who have received an SMN-targeted therapy and could be eligible for treatment with apitegromab [23] Company Strategy and Development Direction - The company aims to be a global biotech powerhouse, leveraging its expertise in myostatin biology to deliver transformative therapies for neuromuscular disorders [5][6] - The strategy includes strengthening the balance sheet, adding redundancy to the supply chain, and preparing for a commercial launch of apitegromab [11][24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence that apitegromab will eventually be approved for SMA, emphasizing the urgency to serve the patient community [7][9] - The regulatory challenges faced are viewed as temporary, with significant opportunities ahead to serve patients [11][18] Other Important Information - The company has secured commercial capacity for a second fill-finish facility, expected to commence in Q1 2026, and anticipates submitting an SBLA for this facility later in 2026 [10][15] - The company is also advancing SRK-439 into clinical development, with an IND cleared by the FDA [17][18] Q&A Session Summary Question: Financing opportunities and operational risks during the transition to a new facility - The company plans to prioritize extending its loan facility for financing, with equity being a last resort [32] - Transitioning to a new facility is expected to be seamless operationally, minimizing risks [34] Question: Confidence in the remediation efforts at the Bloomington facility - Management highlighted the commitment from Novo Nordisk to quality and compliance, expressing optimism about the remediation efforts [40][41] Question: BLA submission strategy and EMA review status - The plan is to submit the BLA after the reinspection of the Bloomington facility, with a decision from the EMA expected by mid-next year [16][49] Question: Timelines for reinspection and potential pivot to a second fill-finish facility - A successful reinspection is crucial, but the company is prepared to pivot to the second facility if necessary [56][57] Question: Disclosure plans regarding the reinspection process - The company will maintain open communication regarding the reinspection timeline and outcomes, sharing material information as it becomes available [74][75]

Financial Data and Key Metrics Changes - Revenue for Q3 2025 increased by 9% year-over-year to $2.8 million, compared to $2.6 million in Q3 2024, driven by strong performance in the shelf-stable product portfolio [14][7] - Gross profit totaled approximately $0.3 million, down from $0.7 million in the prior year, due to higher labor, freight, and raw material costs [14] - Net loss for the quarter was $4 million, compared to a net loss of $2.1 million in Q3 2024 [15] Business Line Data and Key Metrics Changes - The shelf-stable product portfolio grew by 54% year-over-year in Q3, with notable brands like KICK Sports Nutrition, Vitamin Way, Pulp, and Pickle Party contributing to this growth [14][7] - Core herb portfolio saw significant growth, with Hydrobasil up 21% and Wheatgrass up 59% year-over-year [14] Market Data and Key Metrics Changes - The functional food and beverage market is projected to grow from approximately $400 billion to $610 billion by 2030, indicating a strong market opportunity for the company [9] - In the U.S., sales of natural, organic, and functional products are expected to reach $386 billion by 2028, reinforcing the company's strategic alignment with market trends [9] Company Strategy and Development Direction - The company is evolving towards a consumer packaged goods (CPG) model, focusing on non-perishable product expansion and higher-value branded portfolio [7] - Strategic partnerships with major retailers like Kroger and Fresh Market are being strengthened, expanding the company's retail footprint [8] - The company is pursuing new categories such as nutraceuticals, sustainable proteins, and functional foods, guided by a zero-waste approach [12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's positioning for continued growth, emphasizing disciplined execution and product innovation [13] - The current political environment is pushing for less processed foods, creating opportunities for the company to align with consumer demand for clean-label products [28] Other Important Information - The company has refinanced its outstanding debt, securing lower interest rates and more favorable terms, which is expected to reduce annual interest expenses [15] - The company ended the quarter with $0.8 million in cash and equivalents, down from $3.5 million at year-end 2024 [15] Q&A Session Summary Question: Utilization of the Natural Shrimp facility - Management discussed the facility's impressive location and its potential for R&D on next-generation products, including nutraceuticals and food [22][24] Question: Opportunities with grocery stores - Management confirmed that major grocery chains like ShopRite, Kroger, and Fresh Market represent significant opportunities moving into 2026, driven by demand for clean-label products [27][28] Question: Margin related to private label products - Management indicated that while private label products may have lower margins, they provide volume and long-term relationships with major retailers, which are crucial for business growth [31][32]

Financial Data and Key Metrics Changes - Contribution profit for the quarter ended September 30, 2025, was $1.20 million, marking the eighth consecutive positive quarter, with per-booking contribution profit improving by 5% year-on-year to $12.07 [2][3] - Adjusted EBITDA improved by 14% year-over-year, and net loss narrowed to $0.8 million, down from $3.4 million a year ago, representing a significant 76% improvement [3][6] - Revenue for the quarter stood at $2.3 million, reflecting a 2% improvement year-over-year, with contribution margins remaining strong at 52% of reported GAAP revenue [5][9] Business Line Data and Key Metrics Changes - High-quality hosts increased by 46% year-over-year, and repeat users remained consistent at 57%, indicating strong platform stickiness [3][6] - Booking numbers declined marginally by 6%, but gross booking value improved to $6.23 million due to a 22% increase in average booking duration [5][6] Market Data and Key Metrics Changes - The total addressable market for self-drive car-sharing is expected to expand from 18.5 million guests in 2025 to 65 million by 2031, with car ownership in India remaining low at 0.1 cars per household compared to 2.1 in the U.S. [3][4] - With over 1 billion internet users, digital maturity is high, and the contribution margin turnaround from minus $2.5 to plus $12 per booking demonstrates that the model scales profitably [4][10] Company Strategy and Development Direction - The company aims to consolidate its market leadership as the preferred peer-to-peer car-sharing platform, focusing on flexibility over ownership [4][11] - Plans to raise additional capital to fund growth and aim for uplisting by the end of the fiscal year ending March 31, 2026 [7][8] Management's Comments on Operating Environment and Future Outlook - Management highlighted the importance of maintaining contribution profitability while scaling bookings through organic demand, with a focus on sustainable and responsible growth [6][11] - The company is on track towards operating break-even, with a positive trajectory in adjusted EBITDA and improved operational efficiency [10] Other Important Information - The company has managed to keep total liabilities stable, strengthening its balance sheet and improving liquidity [8] - Non-GAAP measures provide a realistic view of performance, with consistent margins above 50% and narrowing losses every quarter [9] Q&A Session Summary - No specific questions or answers were documented in the provided content, thus this section is not applicable.